Literature DB >> 21425451

Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease.

Madhu Gupta1, David Lillicrap, Ann Marie Stain, Kenneth D Friedman, Manuel D Carcao.   

Abstract

Patients presenting with a low FVIII:C and with normal VWF levels are usually presumed to have hemophilia (males) or be carriers for hemophilia (females). Some of these patients may instead have VWD:2N. Such patients if misdiagnosed are likely to suffer from insufficiently treated bleeds. We report 2 males and 1 female who presented with a low FVIII:C (1-21%) and minimally reduced/normal VWF and were assumed to have, or be a carrier for, hemophilia A. Eventually all were found to have VWD:2N. Prior to the correct diagnosis the males had been treated with rFVIII with poor responses and ultimately adverse clinical consequences.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21425451     DOI: 10.1002/pbc.23120

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

1.  Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.

Authors:  B Boylan; A S Rice; C De Staercke; M E Eyster; H M Yaish; C M Knoll; C J Bean; C H Miller
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

Review 2.  Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.

Authors:  Veronica H Flood
Journal:  Semin Thromb Hemost       Date:  2013-12-12       Impact factor: 4.180

3.  Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N.

Authors:  John N Allan; Kenneth D Friedman; Maria T DeSancho
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

Review 4.  Current issues in diagnosis and treatment of von Willebrand disease.

Authors:  Daniel A Keesler; Veronica H Flood
Journal:  Res Pract Thromb Haemost       Date:  2017-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.